Hold-rated reports

904 tickers rated Hold
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Teleflex Incorporated
TFX·Healthcare
B ★★★Hold
Current$150.87
Target$164.10
Return+8.8%
Nov 8, 2026

Teleflex could unlock higher per-share earnings through portfolio simplification, debt reduction, and medical device innovation, but weak capital returns and uncertain recurring margins constrain the investment case.

Score
72
Camden Property Trust
CPT·Real Estate
B ★★★Hold
Current$99.44
Target$106.95
Return+7.6%
Nov 8, 2026

Camden offers dependable apartment rental cash flow, attractive dividends, and recovery potential from disciplined capital recycling, but persistent Sun Belt oversupply and weak same-property NOI growth could delay meaningful FFO expansion.

Score
72
Mattel, Inc.
MAT·Consumer Discretionary
B ★★★Hold
Current$15.35
Target$17.38
Return+13.2%
Nov 8, 2026

Mattel's iconic brands, cash generation, and discounted valuation offer recovery potential, but weakening core toy demand, tariff exposure, and management execution uncertainty limit near-term conviction.

Score
72
A10 Networks, Inc.
ATEN·Technology
B ★★★Hold
Current$24.76
Target$29.67
Return+19.8%
Nov 8, 2026

A10 Networks combines high-margin secure networking, strong cash generation, and accelerating AI-related infrastructure demand, but customer concentration and a demanding valuation limit its margin of safety.

Score
72
Prestige Consumer Healthcare Inc.
PBH·Healthcare
B ★★★Hold
Current$42.98
Target$54.12
Return+25.9%
Nov 8, 2026

Prestige offers undervalued cash-generative OTC healthcare brands with acquisition-driven recovery potential, but elevated leverage and persistent Clear Eyes manufacturing disruptions threaten earnings normalization.

Score
72
Guardian Pharmacy Services, Inc.
GRDN·Healthcare
B ★★★Hold
Current$42.39
Target$45.76
Return+7.9%
Nov 8, 2026

Guardian Pharmacy Services can compound earnings through growing prescription volumes, pharmacy network expansion, and improving operating leverage, but reimbursement pressure and elevated valuation multiples limit the margin of safety.

Score
72
ICU Medical, Inc.
ICUI·Healthcare
B ★★★Hold
Current$172.11
Target$183.35
Return+6.5%
Nov 8, 2026

ICU Medical offers a credible infusion-therapy turnaround supported by recurring consumables and stronger cash flow, but modest ROIC, acquisition-related debt, and product-quality risks limit its margin of safety.

Score
72
HA Sustainable Infrastructure Capital, Inc.
HASI·Financials
B ★★★Hold
Current$38.90
Target$42.25
Return+8.6%
Nov 8, 2026

HASI offers long-term sustainable infrastructure financing growth, attractive adjusted returns, and dividend income at a reasonable valuation, but leverage, project credit risk, and accounting complexity constrain its investment appeal.

Score
72
WillScot Holdings Corporation
WSC·Industrials
B ★★★Hold
Current$18.86
Target$24.88
Return+31.9%
Nov 8, 2026

WillScot offers a discounted recovery opportunity through higher modular fleet utilization and recurring rental growth, but elevated leverage and capital-intensive expansion could delay cash-flow improvement.

Score
72
BGC Group, Inc.
BGC·Financials
B ★★★Hold
Current$10.48
Target$12.80
Return+22.1%
Nov 8, 2026

BGC combines an established institutional brokerage franchise with growing electronic trading platforms and attractive normalized valuation, but substantial stock compensation and FMX execution risks limit conviction.

Score
72
Nexstar Media Group, Inc.
NXST·Communication Services
B ★★★Hold
Current$190.02
Target$220.64
Return+16.1%
Nov 8, 2026

Nexstar's strong cash flow and discounted valuation offer upside as debt declines, but TEGNA litigation, elevated leverage, and secular television audience erosion threaten sustainable shareholder returns.

Score
72
JFrog Ltd.
FROG·Technology
B ★★★Hold
Current$100.98
Target$91.71
Return-9.2%
Nov 8, 2026

JFrog benefits from accelerating cloud adoption, strong enterprise retention, and growing software supply chain security demand, but its premium valuation and substantial stock-based compensation constrain prospective shareholder returns.

Score
72